Quarterly report pursuant to Section 13 or 15(d)

Revenue

v3.22.2.2
Revenue
6 Months Ended
Jun. 30, 2022
Revenue From Contract With Customer [Abstract]  
Revenue

11.

Revenue

Product Revenue, Net

Net product revenue was $1.3 million and $2.0 million for the three and six months ended June 30, 2022. Products are sold primarily to wholesalers and specialty pharmacies.  Revenue is reduced from wholesaler list price at the time of recognition for expected chargebacks, rebates, discounts, incentives, and returns, which are referred to as gross to net (“GTN”) adjustments. These reductions are currently attributed to various commercial arrangements.  Chargebacks and discounts are recognized as a reduction in accounts receivable or as accrued expenses based on their nature and settled through the issuance of credits to the customer or through cash payments to the customer, respectively.  All other returns, rebates, and incentives are reflected as accrued expenses and settled through cash payments to the customer.  Three wholesalers comprised 45%, 32%, and 18% of the Company’s gross revenue for the six months ended June 30, 2022.

 

The following table summarizes activity in each of the Company’s product revenue provision and allowance categories as of June 30, 2022 (in thousands):

 

 

 

Discounts and Chargebacks (1)

 

 

Product Returns (2)

 

 

Rebates and Incentives (3)

 

 

Total

 

Balance as of December 31, 2021

 

$

249

 

 

$

21

 

 

$

1,110

 

 

$

1,380

 

Provision related to current period revenue

 

 

709

 

 

 

24

 

 

 

2,211

 

 

 

2,944

 

Changes in estimate related to prior period revenue

 

 

 

 

 

 

 

 

 

 

 

 

Credit/payments

 

 

(516

)

 

 

 

 

 

(2,089

)

 

 

(2,605

)

Balance as of June 30, 2022

 

$

442

 

 

$

45

 

 

$

1,232

 

 

$

1,719

 

 

(1)

Discounts and chargebacks include fees for wholesaler fees, prompt pay and other discounts, and chargebacks. Discounts and chargebacks are deducted from gross revenue at the time revenues are recognized and are included as a reduction in accounts receivable or as an accrued expense based on their nature on the Company’s unaudited condensed consolidated balance sheet.

(2)

Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Company’s unaudited condensed consolidated balance sheet.

(3)

Rebates and incentives include rebates and co-pay program incentives.  Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Company’s unaudited condensed consolidated balance sheets.

 

License Agreement Revenue

In February 2021, the Company entered into an Exclusive License and Collaboration Agreement (the “Agreement”) with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited (collectively, “Hansoh”), pursuant to which the Company granted to Hansoh an exclusive license to research, develop and commercialize ibrexafungerp in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan (the “Territory”).  The Company also granted to Hansoh a non-exclusive license to manufacture ibrexafungerp solely for development and commercialization in the Territory.  For the three and six months ended June 30, 2022, there was no license agreement revenue recognized associated with the Agreement given the variable consideration was fully constrained as of June 30, 2022.   For the six months ended June 30, 2021, the Company recognized license agreement revenue of $12.1 million which included the fixed upfront cash payment of $10.0 million, an additional amount that was payable upon the transfer of certain data related to the manufacturing license, and $1.1 million related to withholding tax obligations that Hansoh remitted on behalf of the Company.